Monte Rosa Therapeutic (GLUE) Piper Sandler 36th Annual Healthcare Conference summary

Platform innovation and differentiation

• QuEEN platform uses proprietary AI and internal data to design molecular glue degraders (MGDs) targeting specific proteins for degradation.

• Ability to predict and reshape ligase surfaces enables targeting of previously undruggable proteins.

• Platform productivity has increased, generating high-quality drug candidates across diverse indications.

• Platform supports a broad pipeline, not limited by druggability constraints.

• Focus is on maximizing impact by selecting optimal targets for development.

Clinical and preclinical pipeline progress

• MRT-2359 targets GSPT1 for MYC-addicted tumors; early phase I data showed safe, effective degradation and hints of activity.

• Dosing regimen shifted from 5/9 to denser 21/7 schedule due to favorable safety profile; next data update expected this quarter.

• Phase II expansion arms planned, with initial signal-finding in defined patient populations.

• MRT-8102, targeting NEK7 for inflammasome-related diseases, plans for IND filing in the first half; pericarditis and gout are key indications considered.

• CDK2 and cyclin E1 MGDs show promise for breast, ovarian, and endometrial cancers, with selective degradation and reduced toxicity.

Strategic partnerships and financial outlook

• MRT-6160 partnered with Novartis for autoimmune diseases; phase I in healthy volunteers ongoing, with top-line results expected in Q1.

• Novartis to lead phase II/III, with a profit share agreement; company retains 30% US revenue share, cost share starts in phase III.

• Roche partnership focuses on discovery of MGDs for novel oncology and neuroscience targets, expanding scientific reach.

• Pro forma cash position near $400 million, with runway into 2028, enabling advancement of multiple programs and internal platform development.